Dawn breaks over the Persian Gulf. U.S. warships glide east-to-west through the Strait of Hormuz — the first since Iran's war machine went quiet — betting big on freedom of navigation to lure back jittery tankers.
Everyone figured cross-border tracking in Mexico would stay a manual slog. RJ Logistics said nope—and made it their edge.
Why settle for clunky cylindrical batteries when you could print power right into your drone's wings? Material's tech sounds revolutionary—until you poke at the fine print.
Ocean carriers barely exhale after a US-Iran ceasefire eases Hormuz fears — now El Niño's forecast slams the Panama Canal with drought risks. Lars Jensen's alert: disruptions could mirror 2023's chaos.
Picture this: a personal scooter that senses doorframes at centimeters away, rerouting before you clip one. Strutt's EV1 isn't just avoiding crashes—it's rewriting mobility for the weary.
Ships stack up like frustrated commuters. FedEx Freight's spin-off clock ticks louder amid whispers of route diversification—just as El Niño eyes the Panama Canal.
A 13% spike in factory utilization. $8 million in projected savings. PPF's switch to ketteQ's tailored planner sounds like a win—but I've seen these 'quick fixes' flop before.
Your next iPhone shipment? It might cost more thanks to a bitter port battle at the Panama Canal. CK Hutchison just fired arbitration shots at Maersk, accusing them of contract betrayal.
Forget smooth sailing. El Niño's drought threat at the Panama Canal means jammed ships, skyrocketing freight rates, and you paying more for basics. Lars Jensen's warning? Spot on.
USPS governors greenlit an 8% hike on key parcel services, hitting shelves April 26. It's billed as temporary — until 2027 — but whispers of deeper fixes loom.
Electric air taxis sound futuristic. Joby Aviation's betting big on custom motors and total control — but history whispers caution.
Panama Canal transits dropped 36% last drought—now El Niño looms. Evergreen's counterpunch: six 24,000-TEU behemoths. Smart hedge or risky bet?
Forget the hype about quick fixes. These tariffs expose pharma's Achilles' heel: 70-80% of APIs from China and India. Chains built for efficiency now face policy bulldozers.
